Every Form 4 that Kyverna Therapeutics (KYTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KYTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYTX filings page.
Kyverna Therapeutics director Ian T. Clark received new equity awards. He was granted 5,093 restricted stock units of common stock, bringing his direct common share holdings to 21,727. He also received options for 20,582 shares at an exercise price of $8.59, expiring in 2036.
Both the RSUs and options will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholders’ meeting, as long as he remains in continuous service through that date.
Kyverna Therapeutics director Fred E. Cohen reported new equity awards and updated holdings. He received 5,093 shares of common stock as a restricted stock unit award, and 20,582 stock options with an exercise price of $8.59 per share.
The RSUs and options will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholder meeting, as long as he remains in continuous service through that date. After the grant, he directly holds 21,727 common shares.
The filing also notes an indirect position of 4,523,924 common shares held by Vida Ventures, LLC. Vida Ventures Advisors, LLC serves as investment advisor, and Dr. Cohen and two others may be deemed to share voting and dispositive power but each disclaims beneficial ownership beyond any pecuniary interest.
Kyverna Therapeutics, Inc. director Beth C. Seidenberg reported equity compensation awards rather than open-market trading. She received 5,093 shares of common stock as a restricted stock unit grant, bringing her directly held common stock to 21,727 shares after the award.
She also received a stock option for 20,582 shares of common stock at an exercise price of $8.59 per share, all of which remain outstanding. Both the restricted stock units and the option will fully vest on the earlier of May 27, 2027, or immediately before Kyverna’s 2027 annual stockholder meeting, assuming her continuous service.
Separately from these direct holdings, entities associated with Westlake BioPartners report indirect ownership of 869,317 shares and 3,787,940 shares of Kyverna common stock. Seidenberg has voting and dispositive control over the relevant general partners but disclaims beneficial ownership except for any pecuniary interest.
Kyverna Therapeutics, Inc. Executive Chairperson Christi Shaw reported a routine tax-related share disposition. On May 27, 2026, 4,194 shares of common stock were withheld and surrendered to the company to cover tax withholding obligations arising from a restricted stock unit (RSU) vesting.
The footnote explains this was tied to an RSU award for 16,634 shares that vested in full on May 27, 2026. After the tax-withholding transaction, Shaw directly holds 66,741 shares of Kyverna Therapeutics common stock.
Kyverna Therapeutics director Aktar Mert reported equity awards consisting of restricted stock units and stock options. The filing shows a grant of 5,093 shares of Common Stock as restricted stock units that vest in full on the earlier of May 27, 2027, or immediately before the company’s 2027 annual stockholder meeting, if service continues through that date. Mert also received stock options covering 20,582 shares of Common Stock at an exercise price of $8.59 per share, which become fully vested and exercisable on the same timeline. Following the restricted stock grant, Mert holds 21,727 shares of Common Stock directly.
Kyverna Therapeutics, Inc. reported that Chief Financial Officer Gregory S. Martini received a grant of stock options covering 325,000 shares of common stock. The options have an exercise price of $8.54 per share and expire on May 18, 2036. One quarter of the option grant vests on May 18, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on his continuous service. Following this compensation-related award, Martini holds 325,000 derivative securities directly, with no open-market purchases or sales reported in this filing.
Kyverna Therapeutics granted Chief Commercial Officer Nadia Dac a stock option to acquire 300,000 shares of common stock at an exercise price of $9.00 per share, expiring on May 4, 2036. This is a compensation award, not an open-market share purchase.
One quarter of the option vests on May 4, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continuous service with the company.
Kyverna Therapeutics, Inc. reported that its Chief Financial Officer, Marc Grasso, received new equity awards as part of his compensation. He was granted a stock option for 65,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. He also received 10,000 shares of common stock in the form of a restricted stock unit award.
According to the vesting terms, one quarter of the restricted stock units will vest on March 13, 2027, with the remaining three quarters vesting in equal annual installments on each one-year anniversary thereafter, subject to his continued service. For the stock option, one quarter of the shares will vest on March 13, 2027, and the remaining shares will vest in equal monthly installments (1/48th each month) thereafter, also contingent on continued service to the company.
Kyverna Therapeutics’ Chief Executive Officer Biddle Warner Weston received new equity awards as part of his compensation. He was granted stock options for 350,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. One quarter of these options vest on March 13, 2027, with the remaining shares vesting in equal monthly installments of 1/48 each month thereafter, contingent on his continuous service.
He also received a restricted stock unit award covering 58,000 shares of common stock. One quarter of this RSU grant vests on March 13, 2027, and an additional one quarter vests on each one-year anniversary after that date, also subject to continued service. Following these awards, his reported holdings include 58,000 shares of common stock and 350,000 options, reflecting compensation-related acquisitions rather than open-market purchases.
Kyverna Therapeutics, Inc. reported that officer Naji Gehchan received new equity awards as part of compensation. He was granted stock options for 105,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. These options vest over time, with one-fourth vesting on March 13, 2027 and the remaining shares vesting in equal monthly installments thereafter, subject to continued service. He also received a restricted stock unit award covering 18,000 shares of common stock, with one-fourth vesting on March 13, 2027 and the rest vesting in equal annual installments, also subject to continued service.
Miller Andrew Craig reported acquisition or exercise transactions in this Form 4 filing.
Kyverna Therapeutics director Andrew Craig Miller reported equity awards consisting of a stock option for 42,945 shares and a restricted stock unit grant for 11,006 shares of common stock. The RSUs vest in three equal annual installments, while the option vests monthly over 36 months, in each case subject to continued service.
Kyverna Therapeutics director Emany Sravan Kumar received new equity awards. On February 24, 2026, Kumar was granted a stock option for 42,945 shares at an exercise price of $0.00 per share and 11,006 shares of common stock as a restricted stock unit award.
The restricted stock units are scheduled to vest in three equal annual installments on each one-year anniversary of the grant date, subject to continued service. The stock option is scheduled to vest in 36 equal monthly installments starting from the grant date, also conditioned on continued service to the company.
Kyverna Therapeutics’ Chief Technology Officer, Mayobanex Pujols, received a grant of stock options for 300,000 shares of common stock on February 9, 2026, with an exercise price of $8.08 per share. These options were acquired as a compensatory award and are held directly.
According to the vesting terms, one-fourth of the option shares vest on February 9, 2027. The remaining shares vest in 1/48th increments each month thereafter, contingent on Pujols’ continuous service with Kyverna through each vesting date. After this grant, he beneficially owns 300,000 derivative securities in the form of these options.
Kyverna Therapeutics Executive Chairperson Shaw Christi reported new equity awards from the company. On January 12, 2026, Shaw Christi received 30,000 shares of common stock as a restricted stock unit award, which vests in four equal annual installments starting January 12, 2027, subject to continued service.
She also received 24,301 performance restricted stock units that vest only if Kyverna’s common stock reaches specified share price targets. In addition, she was granted a stock option for 185,000 shares of common stock at an exercise price of $8.23 per share, with one quarter vesting on January 12, 2027 and the remainder vesting monthly thereafter, conditioned on continued service. Following these awards, she beneficially owned 70,935 shares of common stock and 185,000 stock options directly.
Kyverna Therapeutics' chief technology officer reported an option exercise and share sale in Kyverna Therapeutics, Inc. common stock. On 12/15/2025, the officer exercised stock options to acquire 23,998 shares at an exercise price of $4.83 per share and, on the same date, sold 23,998 shares at $12.2 per share. After these transactions, the officer beneficially owned 22,636 shares of common stock directly and held 85,865 stock options.
The filing states that these trades were made under a Rule 10b5-1 trading plan adopted on September 12, 2025, which automates transactions according to preset instructions. The option originally vested 25% of the shares on January 1, 2025, with the remaining portion vesting in equal monthly installments, contingent on continued service.